SANTA CLARA--Affymetrix and Oncormed announced they will codevelop a gene expression database as a tool to enable the use of gene expression data in drug development by third party subscribers. The new agreement further leverages Oncormed's strength in gene characterization and pharmacogenomics with Affymetrix's GeneChip expression analysis tools. The collaboration is the third in a series of agreements between the companies, representing a relationship that began with the development and validation of a GeneChip assay for identifying mutations in the p53 gene.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.